Dear Reader, I'm sure a lot of folks saw COVID-19 as a potential investment goldmine. They probably thought they could throw money into any company that had started to work on a vaccine and make an easy fortune. We knew better. That's why today we're unveiling what we believe could be the lucrative, low-risk and "crash-proof" COVID trade recommendation you've been waiting for. It's a small American biotech that's not making PPE or developing a vaccine. Instead, they could be on the verge of receiving FDA Emergency Use Authorization for proprietary technology that could have an immediate impact on slowing the spread of the virus across America. And when they do, I fully expect this under-the-radar stock could absolutely surge as much as 565% or more over the next 6 months. In the longer term, we could be looking at a 10-bagger here – 1,000%+ gains. The sky's the limit really. This FDA authorization could be handed down in just a matter of weeks. And that makes this opportunity beyond urgent. I recently filmed an emergency webinar to provide all the details to Stansberry readers. I highly recommend you check it out here, while you still can. Sincerely, Dave Lashmet
Senior Analyst, Stansberry Research | 